R-Configured Amino Acid Derivatives Without Sedative Burden
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiepileptic drugs have limited effectiveness across various types of seizures, often cause sedative side effects, and fail to address coexisting disorders like depression and anxiety, with significant drug resistance in 30-40% of cases.
Innovation Solution
Development of structurally modified amino acid derivatives, specifically compounds with R-configuration, that exhibit broad anticonvulsant, antidepressant, and anxiolytic activities without sedative effects, effective in various seizure types and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiepileptic drugs are used, then seizure control is achieved, but sedative side effects occur
Solution Approach 1:
The patent segments the therapeutic function into two distinct components: anticonvulsant activity and antidepressant/anxiolytic activity. The compounds are designed to provide seizure control through one mechanism while simultaneously addressing mood disorders through a different mechanism, thereby eliminating the need to choose between effective seizure control and avoiding sedative effects.
Solution Approach 2:
The patent changes the chemical structure parameters of amino acid derivatives by modifying side chains and functional groups to achieve broad-spectrum anticonvulsant activity across multiple seizure types while maintaining lack of sedative effects and adding antidepressant/anxiolytic properties.
2Adaptability or versatility
If broad-spectrum antiepileptic coverage is pursued, then multiple seizure types are treated, but drug resistance persists in 30-40% of cases
Solution Approach 1:
The patent creates compounds with universal anticonvulsant activity that functions across multiple seizure types (tonic-clonic, absence, focal, myoclonic) and simultaneously provides antidepressant and anxiolytic effects. This multi-functionality addresses the limitation of current drugs that are often dedicated to specific epilepsy types, potentially overcoming drug resistance through alternative mechanisms of action.
3Reliability
If drugs affecting central GABAergic conductance are used, then seizure control is improved, but mood deterioration occurs
Solution Approach 1:
The patent segments the pharmacological effects to separate seizure control from mood effects. Instead of relying solely on GABAergic modulation which causes mood deterioration, the compounds provide anticonvulsant activity through amino acid derivative mechanisms while simultaneously providing antidepressant/anxiolytic activity through different pathways, thus preventing mood deterioration.
4Object-affected harmful factors
If sedative effects are reduced, then quality of life improves, but anticonvulsant effectiveness may be compromised
Solution Approach 1:
The patent changes the chemical parameters of amino acid derivatives to achieve a unique profile where anticonvulsant effectiveness is maintained or enhanced while sedative effects are eliminated. The structural modifications enable broad-spectrum seizure protection without the sedative burden that typically accompanies effective anticonvulsant therapy.
Data Source
AI summary
2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2-oxopyrrolidin-1-yl)propanamide derivatives with R-configuration at the stereogenic center are disclosed, showing broad-spectrum protective activity in animal models of epileptic seizures, pain, depression and anxiety that are simultaneously devoid of undesirable sedative effects. Additionally, the disclosed derivatives have neuroprotective effects in the in vitro and in vivo studies.